Share on LinkedInShare on LinkedIn

ARTICLE · 21 JANUARY 2025

Effect Of Trips In India

Khurana & Khurana, Advocates and IP Attorneys
Explore more from Khurana & Khurana, Advocates and IP Attorneys

Because of the TRIPS Agreement, the Indian pharmaceutical industry was been confronted with a slew of new obstacles.

IndiaIntellectual Property

INTRODUCTION

Because of the TRIPS Agreement, the Indian pharmaceutical industry was been confronted with a slew of new obstacles. The institutional elements that had fostered the industry's expansion were altered by a 1970 modification to the Patent Act that introduced product patents. The legislation was expected to have a detrimental impact on India and stifle the growth of the country's pharmaceutical industry because it would no longer be allowed to reverse-engineer or export medications with product patents in place. India amended Patents Act, 1970 from time to time in the years 1995, 1999, 2002, and 2005 to meet its obligations under the TRIPS agreement after signing the TRIPS agreement and becoming a member of the Agreement establishing the World Trade Organization (WTO) for the purpose of reducing distortions and functional constraints to international trade and promotion of effective protection of intellectual property rights. Patents Act of 1970, has also

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from